Indo-Bangla Pharmaceuticals Limited

DSE:IBP Stock Report

Market Cap: ৳1.6b

Indo-Bangla Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Indo-Bangla Pharmaceuticals's earnings have been declining at an average annual rate of -47.5%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 20.4% per year.

Key information

-47.5%

Earnings growth rate

-48.8%

EPS growth rate

Pharmaceuticals Industry Growth11.0%
Revenue growth rate-20.4%
Return on equity-1.1%
Net Margin-8.5%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Indo-Bangla Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DSE:IBP Revenue, expenses and earnings (BDT Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24212-18320
31 Dec 23296-8440
30 Sep 23338-10650
30 Jun 233748680
31 Mar 23375-351280
31 Dec 22416-221240
30 Sep 2244771090
01 Jul 22485251110
31 Mar 22619117920
31 Dec 216541181030
30 Sep 217311351210
01 Jul 217821351400
31 Mar 217881051340
31 Dec 208431371380
30 Sep 208621501350
30 Jun 208661561330
31 Mar 208531861350
31 Dec 198281831320
30 Sep 197901701300
30 Jun 197411551270
31 Mar 197421341150
31 Dec 186951171130
30 Sep 186671021160
30 Jun 18660981150
31 Mar 18641891150
30 Jun 17617881090
31 Mar 17581931010
30 Jun 1644559920
01 Jul 1543560850

Quality Earnings: IBP is currently unprofitable.

Growing Profit Margin: IBP is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IBP is unprofitable, and losses have increased over the past 5 years at a rate of 47.5% per year.

Accelerating Growth: Unable to compare IBP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IBP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.6%).


Return on Equity

High ROE: IBP has a negative Return on Equity (-1.13%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.